Cardiovascular Devices Market to Hit $110B by 2029
The global cardiovascular devices market, valued at US$72.83 billion in 2023, is projected to reach US$110.39 billion by 2029,...
Jon Napitupulu
Gamma Delta T Cell Cancer Therapy Clinical Trials Overview
The global gamma delta T cell therapy market is experiencing rapid growth, driven by over 30 therapies currently in...
Targeted Alpha Therapy Clinical Trials: An Overview
Over 20 alpha therapies are currently in clinical trials, marking a significant advancement in targeted cancer treatment. These therapies...
First Canadian Clinic Offers C2N’s PrecivityAD2 Blood Test for Alzheimer’s
The Toronto Memory Program (TMP) is the first clinic in Canada to offer C2N Diagnostics‘ PrecivityAD2 blood test for...
Fresenius Kabi’s Adaptive Nomogram Gets FDA 510(k) Clearance
Fresenius Kabi received FDA 510(k) clearance for its Adaptive Nomogram, an algorithm designed to optimize plasma collection efficiency for...
Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive clinical data from its intranasal human abuse potential (HAP) study of cebranopadol. The study demonstrated...
Cebranopadol Shows Low Abuse Potential in Clinical Trial
Tris Pharma announced positive results from a Phase 1 intranasal human abuse potential (HAP) study of cebranopadol. The study...
Tevogen Bio Secures $10M Grant Funding
Tevogen Bio (Nasdaq: TVGN), a clinical-stage immunotherapy biotech company, has secured up to $10 million in non-dilutive grant funding...
Silexion Shows Strong Tumor Reduction in Pancreatic Cancer Models
Silexion Therapeutics announced positive preclinical data for SIL-204, its RNAi therapeutic candidate targeting KRAS-driven cancers. The data validates systemic...
March Biosciences Gets FDA Orphan Drug for Lymphoma
March Biosciences received FDA orphan drug designation for MB-105, its CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma....